BALTIMORE, Jan. 8, 2024
/PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX)
company, has entered into a collaboration with Alliance Foundation
Trials, LLC (AFT) for research use of Haystack Oncology's
personalized MRD technology (Haystack MRD™) to analyze therapeutic
response and provide molecular insights for AFT's interventional,
randomized phase II clinical trial (AFT-57) in patients with
unresectable stage III non-small cell lung cancer (NSCLC). The
AFT-57 clinical study is supported by Genentech, a member of the
Roche Group, and will explore the efficacy and safety of an
anti-PD-L1 atezolizumab (Tecentriq®) with or without tiragolumab
(anti-TIGIT) in conjunction with chemoradiotherapy.
![Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics Incorporated) Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics Incorporated)](https://mma.prnewswire.com/media/200883/quest_diagnostics_incorporated_logo_logo.jpg)
"This research collaboration with AFT is a great opportunity to
further explore the benefits of using highly sensitive and specific
ctDNA analysis as a means to evaluate the efficacy of novel
therapeutic approaches," said Dan
Edelstein, Vice President and General Manager of Haystack
Oncology. "Haystack MRD was purpose-built to detect ctDNA with
unparalleled sensitivity, making it well-positioned to support the
innovation of new treatment regimens."
"AFT is excited to work with Haystack Oncology to investigate
promising new immunotherapy-based treatments in nationwide
randomized cancer clinical trials," said David Kozono, MD, PhD, AFT Executive Officer and
Alliance Immuno-Oncology Committee Co-Chair. "The new MRD
technology, in conjunction with these novel therapies, offers a
unique opportunity to significantly impact the lives of patients
with inoperable locally advanced non-small cell lung cancer."
About Haystack Oncology
Haystack Oncology represents
the culmination of over 20 years of technical and clinical
development in liquid biopsy technologies by cancer genomics
pioneers at Johns Hopkins School of
Medicine. The company, a wholly owned subsidiary of Quest
Diagnostics, developed Haystack MRD™, a next generation tumor
informed approach for the measurement of minimal residual disease.
Haystack MRD uses an error-corrected ctDNA technology to detect
down to one ctDNA molecule in a million. Haystack Oncology works
with biopharmaceutical companies to advance important therapeutics
to global markets, from early phase clinical development to
companion diagnostics. By detecting patients with measurable
disease for enrollment, and helping to identify early treatment
response and disease clearance as endpoints for treatment efficacy,
Haystack Oncology can accelerate and improve the efficiency of
clinical development programs. Haystack Oncology testing is CLIA
certified in the US and is available for biopharmaceutical clinical
development in laboratories located in Baltimore, Maryland, Hamburg, Germany and Helsinki, Finland. Learn more at
haystackoncology.com.
About Quest Diagnostics
Quest Diagnostics empowers
people to take action to improve health outcomes. Derived from the
world's largest database of clinical lab results, our diagnostic
insights reveal new avenues to identify and treat disease, inspire
healthy behaviors and improve health care management. Quest
annually serves one in three adult Americans and half the
physicians and hospitals in the United
States, and our nearly 50,000 employees understand that, in
the right hands and with the right context, our diagnostic insights
can inspire actions that transform lives.
www.QuestDiagnostics.com.
About Alliance Foundation Trials, LLC
Alliance
Foundation Trials, LLC (AFT) is a research organization that
develops and conducts cancer clinical trials, working closely with
the Alliance for Clinical Trials in Oncology scientific
investigators and institutional member network, research
collaborators, and non-NCI funding sources. AFT seeks to fulfill
the vision of the Alliance for Clinical Trials in Oncology to
reduce the impact of cancer on people by uniting a broad community
of scientists and clinicians from many disciplines committed to
discovering, validating and disseminating effective strategies for
the prevention and treatment of cancer. To learn more about AFT
studies, visit AllianceFoundationTrials.org.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/haystack-oncology-and-alliance-foundation-trials-collaborate-to-use-haystack-mrd-technology-in-phase-ii-clinical-trial-for-unresectable-stage-iii-nsclc-302027787.html
SOURCE Quest Diagnostics